Pharma firms likely to post 11% growth in sales, EBITDA in Q1FY26: Report
New Delhi [India]July 6 (Memorial): According to a report of Kotak Corporate Stocks, pharmaceutical firms are expected to record 11 % growth in the first quarter of the 2026 financial year in the first quarter of 2026 financial years.
However, in April and March, the report added that silent domestic demand may balance the gains a little bit.
Hospitals segment, increasing uprisings, new bed additions and a modest increase in Arpob supported both sales and EBITDA is expected to see a growth of 17 % annually.
In diagnoses, volume growth, better mixture and merger and purchasing activity are expected to contribute to a 14 percent increase in sales throughout the scope.
“For Pharma Companies, we expect the traction in most markets to provide a growth of 11/11% in total sales/EBITDA at 1QFY26.”
The pharmaceutical market for the 2023-24 fiscal year of India is worth $ 23.5 billion worth of domestic consumption and exports worth US $ 26.5 billion.
The local pharmaceutical industry is considered to be the third largest in the world and 14th in terms of production value. The Indian pharmaceutical industry has a strong existence at a global level with a highly diversified product base covering generic drugs, pile drugs, overnight drugs, vaccines, biobenzers and biology.
National Accounts Statistics published by the Ministry of Statistics and Program Application According to 2024, the total output for the industry, ie medicines, medical and botanical products are RS. 4,56,246 CRORES FOR 2022-23 FINANCIAL YEARS At fixed prices, added value from them La1,75,583 Crore.
According to government data, 9,25,811 people are engaged in pharmaceutical, medical and botanical products industry in the 2022-23 fiscal year.
Innovation in Research and Development (R -C) and Pharmaceuticals Sector is carried out by the number of institutions and organizations under various scientific ministries/departments.
In addition to providing graduate and doctoral education, the Pharmacy Department has established seven National Pharmaceutical Education and Research Institutes (NIPERS) conducting high -level research in various pharmaceutical expertise.
In addition, the department framed the “research and development in the Pharma-Medtech sector in India to encourage R & D on pharmaceutical and medical devices”.
The policy also creates an ecosystem for innovation in the industry in order to create an entrepreneurial environment to create an entrepreneurial environment to create a solid ecosystem to ensure the holistic development of India, Rar and innovation. (MOMENT)
